TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1657501

Group type: EXPERIMENTAL
Intervention: Head-up tilt (60 degrees) in subjects with age-related orthostatic hypotension
Number of subjects: 28

Group type: COMPARATOR
Intervention: Head-up tilt (60 degrees) in healthy elderly control subjects
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cold stress and sustained isometric exercise in both groups
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Head-up tilt in subjects with autonomic neuropathy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of noradrenaline, adrenaline, and neuropeptide-Y-like immunoreactivity after head-up tilt
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Aorto-iliac pulse wave velocity index in subjects with age-associated orthostatic hypotension
Number of subjects: 28
Study: 7048929

Group type: EXPERIMENTAL
Intervention: Long course of ampicillin (3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short course of ampicillin (three doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29553432

Group type: EXPERIMENTAL
Intervention: General anaesthesia (20% intravenous propofol for induction, atracurium for muscle relaxation, nitrous oxide and oxygen for maintenance)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Spinal anaesthesia (0.5% hyperbaric solution bupivacaine with 20 μg fentanyl intrathecally)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 181

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 181
Study: 27814862

Group type: EXPERIMENTAL
Intervention: Pilates group (PG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional exercise group (TG)
Number of subjects: 31
Study: 24235775

Group type: EXPERIMENTAL
Intervention: Intermittent maximal lactate steady state (MLSSint = 15.26 ± 0.97 km/h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous maximal lactate steady state (MLSScon = 14.53 ± 0.93 km/h)
Number of subjects: 10
Study: 22699241

Group type: EXPERIMENTAL
Intervention: Early skin-to-skin contact (SSC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional care (control)
Number of subjects: 41
Study: 20175608

Group type: EXPERIMENTAL
Intervention: Structural Ecosystems Therapy (SET)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Person-centered therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Community control condition
Number of subjects: 156
Study: 17683868

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective EPO analogues
Number of subjects: 0
Study: 16304166

Group type: EXPERIMENTAL
Intervention: Azithromycin (oral and intravenous doses)
Number of subjects: 12
Study: 11807960

Group type: EXPERIMENTAL
Intervention: Kava (n = 18) for 7 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Valerian (n = 18) for 7 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (n = 18)
Number of subjects: 54
Study: 9684421

Group type: EXPERIMENTAL
Intervention: n-of-1 trial
Number of subjects: 0
Study: 8075030

Group type: EXPERIMENTAL
Intervention: Oophorectomy (or ovarian ablation)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Oophorectomy plus tamoxifen
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Goserelin plus tamoxifen
Number of subjects: 85

Group type: COMPARATOR
Intervention: Oophorectomy (or ovarian irradiation)
Number of subjects: 85
Study: 2802118

Group type: EXPERIMENTAL
Intervention: Propofol infusion (3.93 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam (0.28 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 12
Study: 4404939

Group type: EXPERIMENTAL
Intervention: 1 g ampicillin daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 2 g ampicillin daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 1 g ampicillin daily + 20 mg prednisolone daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 2 g ampicillin daily + 20 mg prednisolone daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 126
Study: 31221534

Group type: EXPERIMENTAL
Intervention: Hp2‐2 phenotype
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Hp1‐1 and Hp1‐2 phenotypes
Number of subjects: 1256
Study: 31445962

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 27158908

Group type: EXPERIMENTAL
Intervention: Benznidazole 5 mg/Kg/day for 60 days (n = 47)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Benznidazole 5 mg/Kg/day open-label (n = 16)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (n = 48)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Benznidazole treatment
Number of subjects: 111
Study: 24602553

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 22429273

Group type: EXPERIMENTAL
Intervention: Oral contraceptive administered 30 minutes after exenatide
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Repeated daily oral contraceptive administration 30 minutes after exenatide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral contraceptive administered 1 hour before exenatide
Number of subjects: 32
Study: 21246844

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Shenmen (HT 7), Baihui (CV 20), Hegu (LI 4), Taichong (LR 3))
Number of subjects: 65

Group type: COMPARATOR
Intervention: Trazodone (oral administration for 4 weeks)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 65
Study: 18979978

Group type: EXPERIMENTAL
Intervention: FV intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Smoking cessation intervention
Number of subjects: 20
Study: 16389212

Group type: EXPERIMENTAL
Intervention: Home-based antismoking socialization program (n = 371) including 5 printed activity guides, parenting tip sheets, child newsletters, and incentives, plus a booster activity guide 1 year later.
Number of subjects: 776

Group type: COMPARATOR
Intervention: Control group (n = 405) received fact sheets about smoking.
Number of subjects: 776

Group type: COMPARATOR
Intervention: Control group (n = 405)
Number of subjects: 776
Study: 14598513

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memantine (NMDA receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of naltrexone and SSRI antidepressants
Number of subjects: 0
Study: 11081320

Group type: EXPERIMENTAL
Intervention: Hyperthyreosis group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 8994010

Group type: EXPERIMENTAL
Intervention: Volumetric method for measuring forearm and hand volumes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water displacement method
Number of subjects: 0
Study: 8309864

Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitors and gemfibrozil (Lopid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Niacin or bile acid-binding resins
Number of subjects: 0
Study: 2453766

Group type: EXPERIMENTAL
Intervention: Birth control vaccine (synthetic peptide antigen representing the aminoacid sequence 109‐145 of the C‐terminal region of the beta subunit of human chorionic gonadotropin)
Number of subjects: 30
Study: 31781701

Group type: EXPERIMENTAL
Intervention: 50% anorganic bovine bone (ABB) and 50% autogenous bone (group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 100% anorganic bovine bone (group B)
Number of subjects: 32
Study: 27967216

Group type: EXPERIMENTAL
Intervention: Externalized ureteral catheter (EUC)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Double-J ureteral stent (DJ)
Number of subjects: 109
Study: 25873214

Group type: EXPERIMENTAL
Intervention: Pink-veneered zirconia abutments (test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-veneered zirconia abutments (control)
Number of subjects: 20
Study: 22782995

Group type: EXPERIMENTAL
Intervention: Normal saline 10 ml/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dopamine 2.5-5 mcg/kg per min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study: 21291445

Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 891

Group type: COMPARATOR
Intervention: Control
Number of subjects: 891
Study: 19278381

Group type: EXPERIMENTAL
Intervention: Effective breastfeeding technique (observed by health visitors)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Single correction of breastfeeding technique
Number of subjects: 570
Study: 16904519

Group type: EXPERIMENTAL
Intervention: AF+C (Accelerated Fractionation with Concurrent Chemotherapy)
Number of subjects: 189

Group type: COMPARATOR
Intervention: CF+C (Conventional Fractionation with Concurrent Chemotherapy)
Number of subjects: 189

Group type: COMPARATOR
Intervention: AF (Accelerated Fractionation)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Both CRT arms (Concurrent Chemoradiotherapy)
Number of subjects: 189
Study: 14634826

Group type: EXPERIMENTAL
Intervention: Symptomatic athletes during exercise (running)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Symptomatic athletes during exercise (cycling)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Asymptomatic athletes during exercise (cycling)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Symptomatic athletes at rest
Number of subjects: 20
Study: 11727017

Group type: EXPERIMENTAL
Intervention: Flatbed scanner
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Film digitizer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Digital camera
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hard copy images
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall image quality
Number of subjects: 40
Study: 8873700

Group type: EXPERIMENTAL
Intervention: Bromocriptine mesylate (12.5 mg/day for 28 days)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (4 weeks)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bromocriptine responders
Number of subjects: 5
Study: 1676367

Group type: EXPERIMENTAL
Intervention: Fenoldopam (100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of fenoldopam and enalapril
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6324161

Group type: EXPERIMENTAL
Intervention: Azlocillin + Amikacin
Number of subjects: 800

Group type: COMPARATOR
Intervention: Cefotaxime + Amikacin
Number of subjects: 800

Group type: COMPARATOR
Intervention: Ticarcillin + Amikacin
Number of subjects: 800
Study: 30856205

Group type: EXPERIMENTAL
Intervention: Nutritional intervention with pictorial representations; three meetings with interactive activities about healthy eating principles, food classification, reading labels, analyzing food advertising, and representations of healthy and unhealthy meals.
Number of subjects: 461

Group type: COMPARATOR
Intervention: Control group; no exposure to any activity
Number of subjects: 461
Study: 30151703

Group type: EXPERIMENTAL
Intervention: Palbociclib for 7 days prior to indicated resection followed by adjuvant palbociclib (Arm 1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Palbociclib without resection (Arm 2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Palbociclib (both arms)
Number of subjects: 22
Study: 26426577

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.1% and clonidine 1.5 μg ml⁻¹ (RC1.5 group; n = 65)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.1% and clonidine 3 μg ml⁻¹ (RC3 group; n = 65)
Number of subjects: 195

Group type: COMPARATOR
Intervention: ropivacaine 0.1% and sufentanil 0.25 μg ml⁻¹ (RS group; n = 65)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Clonidine groups (RC1.5 and RC3)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Clonidine 3 μg ml⁻¹
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 195
Study: 22944391

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/2 mL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pheniramine hydrogen maleate (45.5 mg/2 mL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined group (Dexamethasone and Pheniramine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 21482702

Group type: EXPERIMENTAL
Intervention: Targeted cancer prevention education (audiovisual and written media)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (n = 105)
Number of subjects: 105
Study: 19586514

Group type: EXPERIMENTAL
Intervention: Laser hair removal (LHR) using Nd:YAG laser after surgical excision of PNS, with 3 to 8 sessions (mean 4.87 ± 1.64) over a follow-up period of 12 to 23 months.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no LHR treatment)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Side effects of LHR treatment
Number of subjects: 25
Study: 17197587

Group type: EXPERIMENTAL
Intervention: Teamwork training curriculum based on crew resource management
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Control group (no teamwork training)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Teamwork training
Number of subjects: 1307
Study: 15344695

Group type: EXPERIMENTAL
Intervention: Budesonide, 4 mg/day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intravenous prednisolone, 120 mg/day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: COMPARATOR
Intervention: Oral prednisolone, 30 mg/day
Number of subjects: 68
Study: 11174790

Group type: EXPERIMENTAL
Intervention: Surgical correction of the incompetent superficial femoral vein valve (in 64 extremities)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Phlebectomy (performed in all extremities)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Corrected valves (in 92% of the extremities with corrected valves)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Stable valvular function (in control group)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Increase in superficial femoral vein reflux (in 74% of extremities with progressive clinical dynamics)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Increase in reflux after valvuloplasty (in 50% of extremities)
Number of subjects: 125
Study: 9663215

Group type: EXPERIMENTAL
Intervention: Trabeculectomy-ALT-Trabeculectomy (TAT) sequence
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty-trabeculectomy-trabeculectomy (ATT) sequence
Number of subjects: 591
Study: 7677241

Group type: EXPERIMENTAL
Intervention: Sedating antihistamines (triprolidine, diphenhydramine, clemastine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsedating antihistamines (terfenadine, loratadine, cetirizine, acrivastine, mizolastine, ebastine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2509528

Group type: EXPERIMENTAL
Intervention: recombinant tissue-type plasminogen activator (rt-PA) administration
Number of subjects: 756
Study: 1105174

Group type: EXPERIMENTAL
Intervention: L-PAM
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 31404623

Group type: EXPERIMENTAL
Intervention: Diabetes-specific care (n = 88)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Usual care (n = 88)
Number of subjects: 176
Study: 28064150

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Risk prediction model (C-index = 0.693)
Number of subjects: 21105
Study: 25400062

Group type: EXPERIMENTAL
Intervention: Prasugrel plus aspirin for 30 months
Number of subjects: 2191
Study: 23873976

Group type: EXPERIMENTAL
Intervention: High-dose nicotine patch therapy (42mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 52
Study: 21602625

Group type: EXPERIMENTAL
Intervention: Internet-based training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional instructor-led training
Number of subjects: 0
Study: 19199072

Group type: EXPERIMENTAL
Intervention: Intralesional verapamil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Local saline injection (control)
Number of subjects: 80
Study: 16970513

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 24000

Group type: COMPARATOR
Intervention: Desloratadine
Number of subjects: 24000
Study: 15381871

Group type: EXPERIMENTAL
Intervention: 99mTc rhenium colloid
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 99mTc phytate
Number of subjects: 200
Study: 11104593

Group type: EXPERIMENTAL
Intervention: EPA-EE (6 g/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (OA-EE; 6 g/d)
Number of subjects: 33
Study: 9048692

Group type: EXPERIMENTAL
Intervention: Non-cancer outpatients (OPG1, OPG2, OPG3)
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: Non-cancer outpatients (OPG3)
Number of subjects: 1231

Group type: COMPARATOR
Intervention: General population (CRG)
Number of subjects: 1231
Study: 8363004

Group type: EXPERIMENTAL
Intervention: Smoking (smokers)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (up to three or four drinks per day)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 417
Study: 3088506

Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ftorafur
Number of subjects: 45
Study: 28987023

Group type: EXPERIMENTAL
Intervention: Soluble hyaluronic acid (HA) microneedle patch plus adenosine wrinkle cream
Number of subjects: 84

Group type: COMPARATOR
Intervention: Soluble hyaluronic acid (HA) microneedle patch alone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Adenosine wrinkle cream alone
Number of subjects: 84
Study: 27618935

Group type: EXPERIMENTAL
Intervention: Musical intervention applied during all NIV sessions
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sensory deprivation during all NIV sessions
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Musical intervention
Number of subjects: 99
Study: 24928294

Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship audit-and-feedback intervention
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (non-ICU services without intervention)
Number of subjects: 6
Study: 22397651

Group type: EXPERIMENTAL
Intervention: Continue donepezil
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 295

Group type: COMPARATOR
Intervention: Discontinue donepezil
Number of subjects: 295

Group type: COMPARATOR
Intervention: Donepezil and memantine combination
Number of subjects: 295
Study: 20142596

Group type: EXPERIMENTAL
Intervention: Individualized prescribed total tumor dose (TTD) based on normal tissue dose constraints (mean lung dose, 19 Gy; maximal spinal cord dose, 54 Gy) up to a maximal TTD of 79.2 Gy in 1.8 Gy fractions twice daily
Number of subjects: 166
Study: 18241646

Group type: EXPERIMENTAL
Intervention: Artesunate combined with NP (vinorelbine and cisplatin)
Number of subjects: 120

Group type: COMPARATOR
Intervention: NP (vinorelbine and cisplatin) alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Artesunate combined with NP
Number of subjects: 120

Group type: COMPARATOR
Intervention: NP alone
Number of subjects: 120
Study: 15821265

Group type: EXPERIMENTAL
Intervention: Antiviral drug therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiviral drug prophylaxis
Number of subjects: 0
Study: 12349850

Group type: EXPERIMENTAL
Intervention: Insulin resistance treatment with new drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin resistance
Number of subjects: 0
Study: 10368053

Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate (8.5% w/w) delivered subgingivally in a biodegradable polymer (DH)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo control (VC)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Oral hygiene (OH)
Number of subjects: 411
Study: 8665547

Group type: EXPERIMENTAL
Intervention: Pramipexole (4.5 mg/day maximum)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: COMPARATOR
Intervention: Pramipexole and Placebo
Number of subjects: 55
Study: 2183619

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 263

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: All groups (Methyldopa, Labetalol, No medication)
Number of subjects: 263
Study: 7438713

Group type: EXPERIMENTAL
Intervention: Passive ventilation in a Drinker respirator
Number of subjects: 5

Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 5
Study: 31964446

Group type: EXPERIMENTAL
Intervention: Endoscopic butterfly-inlay cartilage myringoplasty
Number of subjects: 71

Group type: COMPARATOR
Intervention: Endoscopic push-through myringoplasty
Number of subjects: 71
Study: 30111233

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) classes
Number of subjects: 26

Group type: COMPARATOR
Intervention: Electronic Tablet (ET) classes
Number of subjects: 26
Study: 28072852

Group type: EXPERIMENTAL
Intervention: Peer education intervention consisting of three sessions held by peers.
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 179
Study: 25864242

Group type: EXPERIMENTAL
Intervention: Combined in-office and home-use desensitizing system containing 8% arginine and calcium carbonate (Test)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional prophylactic paste and potassium nitrate dentifrice (Control)
Number of subjects: 50
Study: 24026600

Group type: EXPERIMENTAL
Intervention: Pay-for-performance incentives in EHR-enabled clinics
Number of subjects: 42